News

Public · Published

INO: VOCERYQ wins FDA approval to reduce surgery frequency in adults with RRP

VOCERYQ received FDA Accelerated Approval to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP). In the FDA efficacy population, 27% needed no surgery during the 12 months after the dosing window. A confirmatory study is planned.

Published:

Updated:

What happened

VOCERYQ received FDA Accelerated Approval to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP). In the FDA efficacy population, 27% needed no surgery during the 12 months after the dosing window. A confirmatory study is planned.

Confirmed

Global impact / market context

The approval may let Inovio offer VOCERYQ to adults who otherwise face repeated procedures, creating a possible route to treatment revenue. Whether that opportunity becomes meaningful depends on how widely doctors use it and whether the planned study supports the early approval.

Analyst inference

Accelerated Approval allows a medicine to reach patients based on early evidence while further study is still needed. The 27% figure applies only to the FDA efficacy population, not necessarily all patients, so sales potential and confidence in sustained benefit remain uncertain.

Analyst inference

What to watch

  1. Watch for details on the planned confirmatory study, including its start, design, and results; these will help establish whether VOCERYQ’s benefit is supported by further evidence. Confirmed
  2. Track whether Inovio reports treatment uptake or revenue contribution, which would show whether approval is translating into paid use rather than remaining a regulatory milestone. Analyst inference
  3. Watch for FDA updates on the approval’s status and any required follow-up, since confirmatory evidence may affect the treatment’s future availability. Analyst inference

Evidence

  • Original source link unavailable